• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染 BA.5 后,针对 XBB 奥密克戎亚变种的中和抗体水平较低。

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.

机构信息

Laboratory of Aging Research and Cancer Drug Target, Department of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.

NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China.

出版信息

Signal Transduct Target Ther. 2023 Jun 19;8(1):252. doi: 10.1038/s41392-023-01495-4.

DOI:10.1038/s41392-023-01495-4
PMID:37336889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10279763/
Abstract

The COVID-19 response strategies in Chinese mainland were recently adjusted due to the reduced pathogenicity and enhanced infectivity of Omicron subvariants. In Chengdu, China, an infection wave was predominantly induced by the BA.5 subvariant. It is crucial to determine whether the hybrid anti-SARS-CoV-2 immunity following BA.5 infection, coupled with a variety of immune background, is sufficient to shape the immune responses against newly emerged Omicron subvariants, especially for XBB lineages. To investigate this, we collected serum and nasal swab samples from 108 participants who had been infected in this BA.5 infection wave, and evaluated the neutralization against pseudoviruses. Our results showed that convalescent sera from individuals, regardless of vaccination history, had remarkably compromised neutralization capacities against the newly emerged XBB and XBB.1.5 subvariants. Although post-vaccination with BA.5 breakthrough infection slightly elevated plasma neutralizing antibodies against a part of pseudoviruses, the neutralization activities were remarkably impaired by XBB lineages. Furthermore, we analyzed the impacts of the number of vaccinations, age, and sex on the humoral and cellular immune response after BA.5 infection. Our findings suggest that the neutralization against XBB lineages that elicited by current hybrid immunity after BA.5 infection, are remained at low levels, indicating an urgent need for the development of next-generation of COVID-19 vaccines that designed based on the XBB sub-lineages and other future variants.

摘要

由于奥密克戎亚变种的致病性降低和感染力增强,中国大陆最近调整了 COVID-19 应对策略。在中国成都,由 BA.5 亚变种引发了一波感染。重要的是要确定 BA.5 感染后产生的混合抗 SARS-CoV-2 免疫,加上各种免疫背景,是否足以塑造对新出现的奥密克戎亚变种的免疫反应,特别是对 XBB 谱系。为了研究这一点,我们从 108 名在此次 BA.5 感染浪潮中感染的参与者中收集了血清和鼻腔拭子样本,并评估了对假病毒的中和作用。我们的结果表明,无论接种史如何,个体的恢复期血清对新出现的 XBB 和 XBB.1.5 亚变种的中和能力明显下降。尽管 BA.5 突破性感染后的疫苗接种后略微提高了对部分假病毒的血浆中和抗体,但 XBB 谱系显著损害了中和活性。此外,我们分析了接种次数、年龄和性别对 BA.5 感染后体液和细胞免疫反应的影响。我们的研究结果表明,由当前 BA.5 感染后混合免疫引起的针对 XBB 谱系的中和作用仍然处于低水平,这表明迫切需要开发基于 XBB 亚谱系和其他未来变体的下一代 COVID-19 疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/c824d61f914e/41392_2023_1495_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/08b02cf89529/41392_2023_1495_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/19efb1438970/41392_2023_1495_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/285bd93a6888/41392_2023_1495_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/b3f3be78926b/41392_2023_1495_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/c824d61f914e/41392_2023_1495_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/08b02cf89529/41392_2023_1495_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/19efb1438970/41392_2023_1495_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/285bd93a6888/41392_2023_1495_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/b3f3be78926b/41392_2023_1495_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/c824d61f914e/41392_2023_1495_Fig5_HTML.jpg

相似文献

1
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.感染 BA.5 后,针对 XBB 奥密克戎亚变种的中和抗体水平较低。
Signal Transduct Target Ther. 2023 Jun 19;8(1):252. doi: 10.1038/s41392-023-01495-4.
2
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行,但在 BA.5/ BF.7 突破性感染后,针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
3
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力,但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
4
Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.奥密克戎变异株在坦桑尼亚流行期间评估 COVID-19 基础免疫系列接种后的交叉中和免疫反应。
J Med Virol. 2024 Aug;96(8):e29822. doi: 10.1002/jmv.29822.
5
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.接种疫苗和突破性感染后对奥密克戎亚变体的中和作用持久性。
Cell Rep. 2023 Feb 28;42(2):112075. doi: 10.1016/j.celrep.2023.112075. Epub 2023 Jan 27.
6
Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.奥密克戎 XBB.1.5 和 JN.1 变异株经 COVID-19 加强针接种和感染后的中和作用。
J Med Virol. 2024 Jul;96(7):e29801. doi: 10.1002/jmv.29801.
7
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.奥密克戎 XBB、BR.2 和 BA.2.3.20 亚变种的中和逃逸。
Cell Rep Med. 2023 May 16;4(5):101049. doi: 10.1016/j.xcrm.2023.101049. Epub 2023 Apr 25.
8
Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.BA.2.86 逃避免疫与 BA.5 和 BA.5-XBB 恢复期亚群血浆中的 XBB 亚系相当。
J Med Virol. 2024 Jan;96(1):e29417. doi: 10.1002/jmv.29417.
9
Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.接种含BA.4/5的二价mRNA疫苗个体的血清对奥密克戎亚变体BN.1和XBB.1.5的中和活性较低。
Immune Netw. 2023 Nov 13;23(6):e43. doi: 10.4110/in.2023.23.e43. eCollection 2023 Dec.
10
Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.对 BNT162b2 二价加强针接种后六个月时针对 XBB.1.5、BA.2.86、FL.1.5.1 和 JN.1 的中和抗体反应。
Int J Infect Dis. 2024 Jun;143:107028. doi: 10.1016/j.ijid.2024.107028. Epub 2024 Apr 5.

引用本文的文献

1
Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1.阿米替林能有效中和包括D614G、奥密克戎BA.5和奥密克戎XBB.1在内的不同严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体。
Front Microbiol. 2025 Aug 4;16:1631947. doi: 10.3389/fmicb.2025.1631947. eCollection 2025.
2
Exploring the Intrinsic Structural Plasticity and Conformational Dynamics of Human Beta Coronavirus Spike Glycoproteins.探索人类β冠状病毒刺突糖蛋白的内在结构可塑性和构象动力学。
J Chem Inf Model. 2025 Jul 28;65(14):7712-7733. doi: 10.1021/acs.jcim.5c00990. Epub 2025 Jul 17.
3
Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections.

本文引用的文献

1
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.奥密克戎 XBB.1.5、CH.1.1 和 CA.3.1 变异株增强了对中和抗体反应的逃避。
Cell Rep. 2023 May 30;42(5):112443. doi: 10.1016/j.celrep.2023.112443. Epub 2023 Apr 18.
2
Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection.奥密克戎亚变体突破性感染或再次感染后对XBB.1和XBB.1.5的中和作用。
Lancet Reg Health West Pac. 2023 Apr 4;33:100759. doi: 10.1016/j.lanwpc.2023.100759. eCollection 2023 Apr.
3
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5.
奥密克戎亚谱系在初次感染和疫苗突破性感染中诱导的差异性免疫。
Sci Rep. 2025 Jul 3;15(1):23718. doi: 10.1038/s41598-025-07702-2.
4
Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months.6个月后老年人对SARS-CoV-2感染的免疫反应降低。
Front Immunol. 2025 May 9;16:1596065. doi: 10.3389/fimmu.2025.1596065. eCollection 2025.
5
Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients.科兴疫苗接种者中针对新冠病毒变异株的RBD-ACE2阻断抗体与结合抗体之间的时间相关性及其在新冠患者中的持久性
Sci Rep. 2025 May 6;15(1):15831. doi: 10.1038/s41598-025-98627-3.
6
A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.一种源自JN.1刺突蛋白的很有前景的mRNA疫苗可针对多种已出现的奥密克戎变体提供保护性免疫。
Mol Biomed. 2025 Mar 4;6(1):13. doi: 10.1186/s43556-025-00258-7.
7
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.一种重组蛋白疫苗可诱导针对SARS-CoV-2 JN.1和XBB谱系亚变体的保护性免疫。
Signal Transduct Target Ther. 2025 Feb 26;10(1):58. doi: 10.1038/s41392-025-02154-6.
8
XBB: the chosen one from SARS-CoV-2 homologous recombination.XBB:新冠病毒同源重组中的“天选之子”
Life Med. 2024 Feb 13;3(2):lnae002. doi: 10.1093/lifemedi/lnae002. eCollection 2024 Apr.
9
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.三价重组蛋白疫苗诱导对XBB谱系和JN.1亚变体的交叉中和作用:临床前和1期临床试验
Nat Commun. 2024 Dec 30;15(1):10778. doi: 10.1038/s41467-024-55087-z.
10
Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1.奥密克戎二价疫苗、既往感染及其诱导的中和抗体对奥密克戎XBB.1.16和EG.5.1所致症状性感染的保护作用。
Open Forum Infect Dis. 2024 Sep 6;11(9):ofae519. doi: 10.1093/ofid/ofae519. eCollection 2024 Sep.
深度中和逃逸和增强的宿主细胞进入是快速传播的新冠病毒谱系XBB.1.5的特征。
Cell Mol Immunol. 2023 Apr;20(4):419-422. doi: 10.1038/s41423-023-00988-0. Epub 2023 Mar 3.
4
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.抗新型冠状病毒变异株奥密克戎XBB.1.5的抗病毒和二价疫苗效力
Lancet Infect Dis. 2023 Apr;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8.
5
Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection.奥密克戎突破性感染灭活疫苗接种者体内 SARS-CoV-2 中和抗体的动力学:推断感染史和持续时间的作用。
Front Immunol. 2023 Jan 24;14:1083523. doi: 10.3389/fimmu.2023.1083523. eCollection 2023.
6
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.XBB.1.5增强传播性中的ACE2结合与抗体逃逸
Lancet Infect Dis. 2023 Mar;23(3):278-280. doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.
7
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.用二价疫苗中和BA.4-BA.5、BA.4.6、BA.2.75.2、BQ.1.1和XBB.1
N Engl J Med. 2023 Mar 2;388(9):854-857. doi: 10.1056/NEJMc2214916. Epub 2023 Jan 25.
8
SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.不同疫苗接种和突破感染组合后 SARS-CoV-2 的体液和细胞免疫。
Nat Commun. 2023 Feb 2;14(1):572. doi: 10.1038/s41467-023-36250-4.
9
Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection.重复接种新冠病毒灭活疫苗会削弱突破性感染中针对奥密克戎变体的中和抗体。
Cell Res. 2023 Mar;33(3):258-261. doi: 10.1038/s41422-023-00781-8. Epub 2023 Jan 25.
10
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种BQ.1.1和XBB.1的显著中和逃逸
N Engl J Med. 2023 Feb 16;388(7):662-664. doi: 10.1056/NEJMc2214314. Epub 2023 Jan 18.